Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Cystatin C as a predictor of all-cause mortality and myocardial infarction in patients with non-ST-elevation acute coronary syndrome

Ristiniemi, Noora ; Lund, Juha ; Tertti, Risto ; Christensson, Anders LU ; Ilva, Tuomo ; Porela, Pekka ; Pulkki, Kari and Pettersson, Kim (2012) In Clinical Biochemistry 45(7-8). p.535-540
Abstract
Objectives: To investigate the predictive value of cystatin C among patients diagnosed with non-ST-elevation acute coronary syndrome (nSTE-ACS). Design and methods: Admission serum samples from 245 nSTE-ACS patients were measured with a novel cystatin C immunoassay based on a dry-reagent, double monoclonal design. Creatinine concentrations, estimated glomerular filtration rates (eGFR) and one-year follow-up data were available for these patients. Results: During the follow-up period, 34 (14%) of patients had myocardial infarction (MI) and 25 (11%) died. Increased serum cystatin C was an independent predictor of all-cause mortality and combined events (all-cause mortality and MI) after adjustment to non-biomarker baseline factors, hazard... (More)
Objectives: To investigate the predictive value of cystatin C among patients diagnosed with non-ST-elevation acute coronary syndrome (nSTE-ACS). Design and methods: Admission serum samples from 245 nSTE-ACS patients were measured with a novel cystatin C immunoassay based on a dry-reagent, double monoclonal design. Creatinine concentrations, estimated glomerular filtration rates (eGFR) and one-year follow-up data were available for these patients. Results: During the follow-up period, 34 (14%) of patients had myocardial infarction (MI) and 25 (11%) died. Increased serum cystatin C was an independent predictor of all-cause mortality and combined events (all-cause mortality and MI) after adjustment to non-biomarker baseline factors, hazard ratio (HR) 2.19 (per increase of 1 tertile; 95% CI 1.28-3.78, p = 0.0046) and 1.75 (1.22-2.51, p = 0.0024), respectively. Corresponding values for eGFR were 2.56 (1.43-4.59, p = 0.0016) and 1.76 (1.23-2.53, p = 0.0022), respectively. Creatinine was not an independent predictor of endpoints (p > 0.05). Conclusions: Cystatin C was associated with an increased risk of death and combined events in patients with nSTE-ACS. (C) 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Acute coronary syndrome, Cystatin C, Kidney, Myocardial infarction, Renal insufficiency, Risk
in
Clinical Biochemistry
volume
45
issue
7-8
pages
535 - 540
publisher
Elsevier
external identifiers
  • wos:000303553300005
  • scopus:84860210769
ISSN
1873-2933
DOI
10.1016/j.clinbiochem.2012.02.012
language
English
LU publication?
yes
id
e0f62c23-421b-4037-9cb2-e13e7d15ae27 (old id 2551645)
date added to LUP
2016-04-01 10:43:05
date last changed
2022-04-20 05:29:43
@article{e0f62c23-421b-4037-9cb2-e13e7d15ae27,
  abstract     = {{Objectives: To investigate the predictive value of cystatin C among patients diagnosed with non-ST-elevation acute coronary syndrome (nSTE-ACS). Design and methods: Admission serum samples from 245 nSTE-ACS patients were measured with a novel cystatin C immunoassay based on a dry-reagent, double monoclonal design. Creatinine concentrations, estimated glomerular filtration rates (eGFR) and one-year follow-up data were available for these patients. Results: During the follow-up period, 34 (14%) of patients had myocardial infarction (MI) and 25 (11%) died. Increased serum cystatin C was an independent predictor of all-cause mortality and combined events (all-cause mortality and MI) after adjustment to non-biomarker baseline factors, hazard ratio (HR) 2.19 (per increase of 1 tertile; 95% CI 1.28-3.78, p = 0.0046) and 1.75 (1.22-2.51, p = 0.0024), respectively. Corresponding values for eGFR were 2.56 (1.43-4.59, p = 0.0016) and 1.76 (1.23-2.53, p = 0.0022), respectively. Creatinine was not an independent predictor of endpoints (p > 0.05). Conclusions: Cystatin C was associated with an increased risk of death and combined events in patients with nSTE-ACS. (C) 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.}},
  author       = {{Ristiniemi, Noora and Lund, Juha and Tertti, Risto and Christensson, Anders and Ilva, Tuomo and Porela, Pekka and Pulkki, Kari and Pettersson, Kim}},
  issn         = {{1873-2933}},
  keywords     = {{Acute coronary syndrome; Cystatin C; Kidney; Myocardial infarction; Renal insufficiency; Risk}},
  language     = {{eng}},
  number       = {{7-8}},
  pages        = {{535--540}},
  publisher    = {{Elsevier}},
  series       = {{Clinical Biochemistry}},
  title        = {{Cystatin C as a predictor of all-cause mortality and myocardial infarction in patients with non-ST-elevation acute coronary syndrome}},
  url          = {{http://dx.doi.org/10.1016/j.clinbiochem.2012.02.012}},
  doi          = {{10.1016/j.clinbiochem.2012.02.012}},
  volume       = {{45}},
  year         = {{2012}},
}